Product nameHuman/Mouse/Rat MEK1 Antibody Pair - BSA and Azide free
See all MEK1 kits
Assay typeELISA set
Range31.25 pg/ml - 2000 pg/ml
Species reactivityReacts with: Mouse, Rat, Human
The Antibody Pair can be used to quantify MEK1. BSA and Azide free antibody pairs include unconjugated capture and detector antibodies suitable for sandwich ELISAs. The antibodies are provided at an approximate concentration of 1 mg/ml as measured by the protein A280 method. The recommended antibody orientation is based on internal optimization for ELISA-based assays. Antibody orientation is assay dependent and needs to be optimized for each assay type. Both capture and detector antibodies are rabbit monoclonal antibodies delivering consistent, specific, and sensitive results.
For additional information on the performance of the antibody pair, see the equivalent SimpleStep ELISA® Kit (ab208988), which uses the same antibodies. However, due to differences in their formulation, this antibody pair cannot be used with the consumables provided with our SimpleStep ELISA Kits. Please note that the range provided for the pairs is only an estimation based on the performance of the related product using the same antibody pair. Performance of the antibody pair will depend on the specific characteristics of your assay. We guarantee the product works in sandwich ELISA, but we do not guarantee the sensitivity or dynamic range of the antibody pair in your assay.
To receive an electronic copy of the Certificate of Analysis, please send an email to technical support with "CoA for matched antibody pair kit" in the subject line and the desired product number and lot number in the body of the email.
Download SDS here.
Tested applicationsSuitable for: ELISAmore details
Storage instructionsStore at +4°C. Please refer to protocols.
Components 10 x 96 tests Human/Mouse/Rat MEK1 Capture Antibody (unconjugated) 1 x 100µg Human/Mouse/Rat MEK1 Detector Antibody (unconjugated) 1 x 100µg
FunctionCatalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates ERK1 and ERK2 MAP kinases.
Tissue specificityWidely expressed, with extremely low levels in brain.
Involvement in diseaseDefects in MAP2K1 are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.
Sequence similaritiesBelongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.
Contains 1 protein kinase domain.
modificationsPhosphorylation on Ser/Thr by MAP kinase kinase kinases (RAF or MEKK1) regulates positively the kinase activity.
Acetylation by Yersinia yopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway.
- Information by UniProt
- Dual specificity mitogen activated protein kinase kinase 1
- Dual specificity mitogen-activated protein kinase kinase 1
- ERK activator kinase 1
Our Abpromise guarantee covers the use of ab242032 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ELISA||Use at an assay dependent concentration.|
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab242032 has not yet been referenced specifically in any publications.